

# IASLC Lung Cancer Immunotherapy Meeting

March 22-25, 2018

Hotel: Meliä Castilla  
Calle del Poeta Joan Maragall, 43  
Madrid, Spain 28020

Organizing Committee: Tony Mok, Roy Herbst, Luis Paz-Ares, David Carbone, Fred R. Hirsch, Giorgio V. Scagliotti, Federico Cappuzzo, Pia Hirsch, Murry Wynes

## Thursday, March 22, 2018

4:00 – 6:00 p.m.	Registration and Reception	
6:00 – 6:30 p.m.	Keynote Speaker I	Laurence Zitvogel
6:30 – 6:45 p.m.	Keynote Speaker II Lung Cancer Treatment Progress: Advocate Perspective	Stefania Vallone
6:45 – 7:00 p.m.	Tobacco and E-cigarette Induced Inflammation	Peter Shields

## Friday, March 23, 2018

8:30 – 9:30 a.m.	<b>Session I: Basic Immunology</b>  <b>Chairs: Licia Rivoltini, TBD</b>	
8:00 – 8:20 a.m.	Basic Immunological Principles	Ignacio Melero
8:20 – 8:40 a.m.	Immunologic Drug Development	Daniel Tan
8:40 – 9:00 a.m.	Discussion	Licia Rivoltini
9:00 – 10:00 a.m.	<b>Session II: Animal Models – Preclinical Studies and Phase I Studies</b>  <b>Chairs: Ignacio Melero, Roy Herbst</b>	
9:00 – 9:15 a.m.	Patient-Derived Tumor Models for Immunotherapy Development	Miguel Sanmamed
9:15 – 9:30 a.m.	Cytokine-Induced Killer Cells as Immunotherapy for Solid Tumors: Current Evidence and Perspectives	Dario Sangiolo
9:30 – 9:45 a.m.	Phase I Studies with Novel Immunotherapeutics	Roy Herbst
9:45 – 10:00 a.m.	Discussion	Roy Herbst
10:00 – 10:15 a.m.	<b>Coffee Break</b>	

**Friday, March 23, 2018**

<b>10:15 a.m. – Noon</b>	<b>Session III: Immunodiagnostics</b>  <b>Chairs: Keith Kerr, Elisabeth Brambilla</b>	
10:15 – 10:35 a.m.	PD-L1	Fred R. Hirsch
10:35 – 10:55 a.m.	Other IHC Markers	Fernando López-Ríos
10:55 – 11:15 a.m.	Mutation Burden (Tumor/Plasma)	David Carbone
11:15 – 11:35 a.m.	Genomic Signatures	Matthew Hellman
11:35 a.m. - noon	Discussion	Keith Kerr
<b>Noon – 1:00 p.m.</b>	<b>Lunch</b>	
<b>1:00 – 2:30 p.m.</b>	<b>Session IV: Immunotherapy – 1<sup>st</sup> Line</b>  <b>Chairs: David Carbone, TBD</b>	
1:00 – 1:15 p.m.	Pembolizumab, Single Agent	Giorgio V. Scagliotti
1:15 – 1:30 p.m.	Nivolumab, Single Agent	David Carbone
1:30 – 1:45 p.m.	Others	Sanjay Popat
1:45 – 2:00 p.m.	What is in the Horizon?	TBD
2:00 – 2:30 p.m.	Discussion	Keunchil Park
<b>2:30 – 4:15 p.m.</b>	<b>Session V: Immunotherapy – 2<sup>nd</sup> Line</b>  <b>Chairs: TBD, James Yang</b>	
2:30 – 2:45 p.m.	No Previous IO	James Yang
2:45 – 3:00 p.m.	Previous IO	Marina Garassino
3:00- 3:15 p.m.	Novel IO-Agents	Enriqueta Felip
3:30 – 3:45 p.m.	Master Protocols	Vassiliki Papadimitrakopoulou
3:45 – 4:15 p.m.	Discussion	Thomas Newsom-Davis
<b>4:15 – 4:30 p.m.</b>	<b>Coffee Break</b>	
<b>4:30 – 6:15 p.m.</b>	<b>Session VI: Novel Combinations in Clinical Trials</b>  <b>Chairs: Luis Paz-Ares, Tony Mok</b>	
4:50 – 5:05 p.m.	IO + Chemotherapy	Matthew Hellman
5:05 – 5:20 p.m.	IO + Targeted Therapy	Tetsuya Mitsudomi
5:20 – 5:35 p.m.	TBD	Vamsidhar Velcheti
5:35 – 6:00 p.m.	Discussion	Tony Mok

**Friday, March 23, 2018**

<b>6:00 – 7:00 p.m.</b>	<b>Session VII: Vaccines</b>  <b>Chairs: Johan Vansteenkiste, Glenn Goss</b>	
6:00 – 6:20 p.m.	Overview	Johan Vansteenkiste
6:20 – 6:40 p.m.	Ongoing Clinical Trials	Glenn Goss
6:40 – 7:00 p.m.	Discussion	Ross Soo
<b>7:30 p.m.</b>	<b>Faculty Dinner</b>	

**Saturday, March 24, 2018**

<b>8:00 – 8:30 a.m.</b>	<b>Registration and Breakfast</b>	
8:30 – 10:30 a.m.	<b>Session VIII: Clinical Management</b>  <b>Chairs: Giorgio V. Scagliotti, TBD</b>	
8:30 – 8:45 a.m.	Dosing Amount and Timing of Doses	Fabrice Barlesi
8:45 – 9:00 a.m.	Optimal Duration of Therapy	TBD
9:00 – 9:15 a.m.	Evaluation and Monitoring of Response	Egbert Smit
9:15 – 9:30 a.m.	Management of Side Effects	Mariano Provencio
9:30 – 9:45 a.m.	Post-PD Continuation of PD-L1/PD-1 Targeted Therapy	David Planchard
9:45 – 10:00 a.m.	Discussion	Daniel Tan
<b>10:00 – 11:45 a.m.</b>	<b>Session IX: Stage III Disease</b>  <b>Chairs: Everett Vokes, Rafal Dziadziuszko</b>	
10:00 – 10:20 a.m.	Radiation and Immunotherapy Overview	Umberto Ricardi
10:20 – 10:40 a.m.	Clinical Impact of PACIFIC	Luis Paz-Ares
10:40 – 11:00 a.m.	Radiotherapy Perspectives	Rafal Dziadziuszko
11:00 – 11:15 a.m.	Other Studies	Everett Vokes
11:15 – 11:45 a.m.	Discussion	Andrea Bezjak
<b>11:45 a.m. – 12:30 p.m.</b>	<b>Lunch</b>	

**Saturday, March 24, 2018**

<b>12:30 – 1:30 p.m.</b>	<b>Session X: Small Cell Lung Cancer and IO</b>  <b>Chairs: Leora Horn, Caicun Zhou</b>	
12:30 – 12:50 p.m.	Overview of Current Studies	Leora Horn
12:50 – 1:10 p.m.	Future Potential Studies and Study Design	Patrick Ott
1:10 – 1:30 p.m.	Discussion	Caicun Zhou
<b>1:30 – 3:00 p.m.</b>	<b>Session XI: Mesothelioma</b>  <b>Chairs: Dean Fennell, Anne Tsao</b>	
1:30 – 1:50 p.m.	Overview of I/O and I/O+CTLA4 Studies	Paul Baas
1:50 – 2:10 p.m.	Early Stage I/O Trials and Combination I/O Trials with Anti-Angiogenics and Arginine Depleting Agents	Anne Tsao
2:10 – 2:30 p.m.	T-Cell Therapy	Joachim Aerts
2:30 – 2:50 p.m.	Mesothelin Targeted and Other Novel Agents	Dean Fennell
2:50 – 3:00 p.m.	Discussion	Anne Tsao
<b>3:00 – 4:30 p.m.</b>	<b>Session XII: Early Stage NSCLC</b>  <b>Chairs: Yi-long Wu, Suresh Ramalingam</b>	
3:00 – 3:30 p.m.	Overview of Current Adjuvant Studies	Suresh Ramalingam
3:30 – 3:45 p.m.	Neo-adjuvant Studies	Jay Lee
3:45 – 4:00 p.m.	Neo-adjuvant Study Design and Endpoints	Paul A. Bunn, Jr.
4:00 – 4:30 p.m.	Discussion	Yi-long Wu
<b>4:30 – 5:00 p.m.</b>	<b>Coffee Break</b>	
5:00 – 6:00 p.m.	<b>Session XIII: Immunoprevention</b>  <b>Chairs: Ignacio Wistuba, Paul A. Bunn, Jr.</b>	
5:00 – 5:20 p.m.	Immunobiology of Preneoplasia	Ignacio Wistuba
5:20 – 5:40 p.m.	Immunoprevention Trials	Paul A. Bunn, Jr.
<b>5:40 – 6:00 p.m.</b>	Discussion	Myung-Ju Ahn
<b>7:00 p.m.</b>	<b>General Dinner</b>	

**Sunday, March 25, 2018**

<b>9:00 a.m. – Noon</b>	<b>Session XIV: Nurses Workshop</b>  <b>Chairs: Kim Rohan, Marianne Davies</b>
<b>9:00 a.m. – Noon</b>	<b>Session XV: Advocate Workshop</b>  <b>Chairs: Maureen Rigney, Csaba L. Dégi</b>